Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis

Pharmacotherapy

Volumn 21, Issue 5, 2001, Pages 528-533

  Kuo, Grace M ^a   Boumpas, Dimitrios T ^b   Illei, Gabor G ^b   Yarboro, Cheryl ^b   Pucino, Frank ^a   Burstein, Aaron H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; FLUDARABINE; FLUOROARABINOFURANOSYLADENINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035023486     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.6.528.34549     Document Type: Article

References (32)

1. Systemic lupus erythematosus: Epidemiology, pathology, and pathogenesis
2. Management of lupus nephritis
3. Immunosuppressive therapy of lupus nephritis
4. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial
5. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
6. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide
7. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy
8. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus
9. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy
10. Perspectives on purine analogues
11. Adverse and beneficial immunological effects of purine nucleoside analogues
12. A pilot study: Use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures
13. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis
14. The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis
15. Progress in the treatment of proliferative lupus nephritis
16. Successful treatment of lupus with fludarabine
17. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia
18. Novel approaches in the treatment of lupus nephritis
19. Fludarabine: A review
20. Fludarabine phosphate (Fludara)
21. Pharmacokinetic study of fludarabine phosphate (NSC 312887)
22. The 1982 revised criteria for the classification of systemic lupus erythematosus
23. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids
24. Application of Akaike's information criteria (A1C) in the evaluation of linear pharmacokinetic equations
25. Measurement of the renal clearance of drugs
26. Some suggestions for measuring predictive performance
27. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia
28. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate
29. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients